Tamrintamab Biosimilar Antibody-Drug Conjugate (DPEP3) for Research

Cat No.: GMP-Bios-ab-547

Pre-Made Tamrintamab biosimilar, Whole mAb ADC, Anti-DPEP3 Antibody: Anti-MBD3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tamrintamab pamozirine, also known as SC-003, is an ADC composed of a proprietary antibody against DPEP3 (dipeptidase 3) also known as MBD3, a glycosylphosphatidylinositol anchored membrane protein from the DPEP family of dipeptidase proteins.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-ab-547-1mg 1mg
GMP-Bios-ab-547-10mg 10mg
GMP-Bios-ab-547-100mg 100mg
GMP-Bios-ab-547-xmg ＞100mg



Product Details

Products Name (INN Index) Pre-Made Tamrintamab biosimilar, Whole mAb ADC, Anti-DPEP3 Antibody: Anti-MBD3 therapeutic antibody
INN Name Tamrintamab
TargetDPEP3
FormatWhole mAb ADC
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusActive
100% SI Structure6vgr:HL:CD
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2018
Year Recommended2019
CompaniesStemcentrx
Conditions Approvedna
Conditions ActiveOvarian cancer;Solid tumours
Conditions Discontinuedna
Development Techna



About target - DPEP3

1. Protein Dipeptidase 3

2. Gene DPEP3

3. Organism Homo sapiens (Human)

Function
Dipeptidase that hydrolyzes cystinyl-bis-glycine. Does not hydrolyze leukotriene D4 (LTD4) into leukotriene E4 (LTE4).

Catalytic activity
an L-aminoacyl-L-amino acid + H2O = 2 an L-α-amino acid
EC:3.4.13.19
Source: Rhea.

2 H2O + L-cystine-bis-glycine = 2 glycine + L-cystine
Source: Rhea.

Cofactor
Zn2+

Activity regulation
Inhibited by L-penicillamine.